---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-014788"
form_type: "8-K"
ticker: "VKTX"
cik: "0001607678"
company_name: "Viking Therapeutics, Inc."
filed_at: "2023-04-26T23:59:59+00:00"
generated_at: "2026-06-16T12:57:30.225053+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Viking Therapeutics Q1 net loss $19.5M; VK2735 shows up to 7.8% weight loss

## Summary
- Net loss $19.5M ($0.25/sh) vs $16.1M ($0.21/sh) in Q1 2022; R&D $11.0M, G&A $9.5M.
- Cash and investments $135.7M at March 31; pro forma with $287.5M offering totals ~$406M.
- VK2735 Phase 1: up to 7.8% mean weight loss from baseline (6% placebo-adjusted); half-life 170-250h; no discontinuations for GI AEs.
- Phase 2b VOYAGE study of VK2809 for NASH fully enrolled; primary endpoint data expected in Q2 2023.
- Phase 1 oral formulation of VK2735 initiated; data expected 2H 2023.

## SEC filing metadata
- accession: 0000950170-23-014788
- form_type: 8-K
- ticker: VKTX
- cik: 0001607678
- company_name: Viking Therapeutics, Inc.
- filed_at: 2023-04-26T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1607678/000095017023014788/0000950170-23-014788-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1607678/000095017023014788/vktx-20230426.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-014788
- JSON: https://secwatch.observer/filing/0000950170-23-014788.json
- Plain text: https://secwatch.observer/filing/0000950170-23-014788.txt

## Key facts
- Earnings Releases
  Viking Therapeutics, Inc. reported financial results for first quarter ended March 31, 2023.
  - Period: first quarter ended March 31, 2023
  - Result: reported results
  source text: announced its financial results for the first quarter ended March 31, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1607678/000095017023014788/0000950170-23-014788-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.